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English Summary 
A wide range of conditions such as spinal cord injury, multiple sclerosis, Parkinson’s 
disease, stroke and several others may lead to neurogenic detrusor overactivity 
(NDO). NDO is characterized by involuntary detrusor contractions during the filling 
phase. In layman terms, the nerves or brain centers controlling the bladder are 
damaged, resulting in loss of bladder control. In most patients, detrusor-sphincter-
dyssynergia, which is the concurrent contraction of the detrusor and the urethral 
sphincter, also develop. Despite of concurrent sphincter contractions, involuntary 
detrusor contractions may lead to both incontinence episodes and to vesicoureter-
al reflux, which in the long term can cause renal failure. 
It has been shown that involuntary detrusor contractions can be abolished by elec-
trical stimulation of the dorsal genital nerve (DGN). While DGN stimulation can be 
applied continuously, it may be painful, the reflex loop may habituate to stimula-
tion, and the bladder fullness is unknown. These problems can be overcome by 
using a sensor to detect the onset of bladder contractions, and use a scheme 
known as conditional stimulation. In this scheme, stimulation is only applied at the 
onset of contractions, and this offers a number of advantages. Firstly, a larger ca-
pacity than when using continuous stimulation can be obtained. Secondly, the 
charge injection is reduces, and so is the risk of habituation of the reflex loop. 
Thirdly, a warning signal can be issued to the patient, informing that it is time to 
empty the bladder when convenient. 
However, for this type of conditional stimulation to work, a sensor capable of ro-
bustly detecting the onset of involuntary contractions is needed. Using a tran-
surethral catheter it was demonstrated that intravesical pressure can be used to 
determine the onset of contractions. This project focused on the development and 
experimental test of an implantable pressure sensor, which would enable a com-
plete implantable neuroprosthesis for treating NDO. In an acute animal model 
(n=6) implantable pressure sensors were placed in the bladder wall. The signals 
obtained from these sensors were as good as intravesical pressure measured using 
a transurethral catheter and external equipment in detecting the onset of contrac-
tions. In chronic animal models (n=4), signals from implantable sensors could be 
obtained only for up to three weeks. Improvements of the sensor towards long-
term implantation may improve these figures. In conclusion, using an implantable 
pressure sensor to detect the onset of detrusor contractions is feasible; for chronic 
applications further development of the sensor is needed. 
vi 
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Dansk Resumé 
En lang række lidelser så som rygmarvsskade, sklerose, Parkinsons og cerebrova-
skulære blodpropper kan føre til neurogen overaktiv blære (NDO). NDO er kende-
tegnet ved ufrivillige blæresammentrækninger i fyldningsfasen. I lægmandstermer 
kan man sige, at de nerver, eller de centre i hjernen som styrer blæren, ødelægges, 
og dermed mistes kontrollen med blæren. De fleste med NDO udvikler også detru-
sor-sphincter-dyssynergi, hvilket vil sige samtidige sammentrækninger af både 
blæremusklen (detrusoren) og lukkemusklen (sphincteren). Til trods for denne 
samtidige sammentrækning af sphincteren, kan ufrivillige blæresammentrækninger 
føre til både inkontinens og til at urin presses tilbage i nyrerne, hvilket på sigt kan 
forårsage nyresvigt. 
Man har vist at man ved at påføre penis- eller klitorisnerven (engelsk: dorsal genital 
nerve, DGN) elektrisk stimulation kan stoppe eller undertrykke ufrivillige blære-
sammentrækninger. Man kan i princippet påføre DGN elektrisk stimulation konti-
nuerligt, men det kan være smertefuldt, refleksbanen kan vænne sig til stimulatio-
nen (hvorved effekten går tabt), og den relative fyldning af blæren er ukendt. Disse 
problemer kan forhindres ved at bruge såkaldt behovsstyret stimulation. Her bliver 
stimulation kun påført i begyndelsen af de ufrivillige blæresammentrækninger, 
hvilket stadig får blæren til at slappe af. Man opnår dog også en række andre forde-
le. For det første kan man opnå større fyldning med denne metode end med konti-
nuerlig stimulation. For det andet reduceres mængden af tilført strøm, og risikoen 
for tilvænning af refleksbanen reduceres ligeledes. For det tredje kan man give 
brugeren en advarsel om at blæren nu er ved at være fuld, og at vedkomne bør 
tømme den ved førstkomne lejlighed. 
For at kunne udføre behovsstyret stimulation er det nødvendigt med en sensor, 
som på en robust måde kan registrere begyndende blæresammentrækninger. Det 
er med urinvejskatetre vist, at man kan bruge blæretrykket til at registrere sam-
mentrækninger, og dermed til at styre stimulationen. I dette projekt har der været 
fokuseret på udvikling og eksperimentel test af en implanterbar tryksensor, som 
potentielt kunne gøre det muligt at lave et fuldt implanterbart system til behand-
ling af NDO. I akutte griseforsøg (n=6) blev implanterbare tryksensorer indsat i 
blærevæggen. Signalerne fra disse sensorer var lige så gode som blæretryk målt 
med et urinvejskateter til at registrere blæresammentrækninger. I kroniske forsøg 
(n=4) kunne signaler fra de implanterede sensorer kun måles i op til 3 uger. Det 
forventes at dette vil kunne forbedres med sensorer forbedret med kronisk implan-
viii 
 
tation for øje. Som konklusion kan siges at brugen af en implanterbar tryksensor til 
at registrere blæresammentrækninger er mulig, dog er yderligere udvikling påkræ-
vet før sådan en sensor kan benyttes som kronisk implantat.  
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Chapter I  
Introduction 
 
I-1 Background and purpose 
Voluntary control of the bladder is learned during early childhood, and is so inte-
grated into daily life that it occurs mostly on a sub-conscious level. And while the 
basic on-off function of the bladder might seem simple, neural control is complex 
and distributed, and consequently, many conditions may lead to loss of control.  
In clinical terms, Overactive Bladder (OAB) is defined as “urgency, with or without 
incontinence, usually with frequency and nocturia” [1]. Patients with this syndrome 
may receive an urodynamic examination with the purpose establishing a diagnosis. 
Detrusor Overactivity (DO) is a diagnosis, based on urodynamic examination, char-
acterized by involuntary detrusor contractions during the filling phase. If the cause 
of DO is determined to be a neurological disorder, the diagnosis is termed neuro-
genic detrusor overactivity (NDO). 
Thus, NDO is the loss of voluntary control of the bladder due to neural lesions, 
causing frequent involuntary bladder contractions. It develops in most patients 
with spinal cord injury (SCI), multiple sclerosis (MS) and Parkinson’s disease (PD) 
[2]. It can also be caused by congenital defects such as spina bifida. Additionally, 
stroke may cause NDO, although the exact neurological cause is still debated [2]. 
The field of bladder management is relatively new. SCI, for instance, was practically 
fatal until the 2nd World War. After the war survival increased dramatically, but 
until the introduction of “Clean Intermittent Self Catheterization” (CISC) in the 
1970’s, kidney failure caused by poor management of NDO was the primary cause 
of death in this patient group [3, 4]. Now, life expectancy is much longer, and man-
agement has changed from life-saving to improving the quality of life, and maximiz-
ing the independence of the patients. Individual patient needs differ, but most 
people with SCI rank bladder and bowel function and sexual function and much 
higher than for instance walking [5]. This demonstrates the significant morbidity 
caused by the condition. There is no data available on the total cost of NDO [6]. 
OAB and incontinence in general are two related symptoms, however, less severe, 
with higher prevalence and lower cost per patient. In 1995, the societal cost of 
incontinence (both urgency and stress incontinence) for individuals aged 65 years 
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or older was found to be $26.3 billion in USA alone [7]. In 2000, the direct cost of 
medication, supplies and care related to OAB was estimated to be $12 billion, also 
in USA [8]. It was found that in the USA, the cost to treat NDO with conventional 
therapy was approximately $100.000 for 10 years, and that by using a neural pros-
thesis, this cost could be halved [9]. With a prevalence of SCI patients in the USA of 
150.000 (see section I-4 in this chapter for further details), this means a potential 
saving of $7.5 billion during a 10 year period, just for SCI patients. The prevalence 
of NDO will be looked at more thoroughly in section I-4 of this chapter. 
One treatment option is a neural prosthesis that applies stimulation to the penile 
or clitoral nerve at the beginning of involuntary bladder contractions. This abolishes 
the contraction and maintains continence for the patient. However, it requires a 
sensor that is able to detect the onset of bladder contractions.  
The aim of this thesis is to investigate whether chronic bladder sensing is possible 
using an implantable pressure sensor placed in the bladder wall. This could enable 
a neural prosthesis based on on-demand nerve stimulation. 
The rest of this first chapter details the anatomy of the lower urinary tract, the 
pathophysiology of NDO, and the conservative treatment options. At the end of the 
chapter, neural prosthesis for treating NDO are described. The second chapter is a 
review of state-of-the-art sensing techniques, together with a discussion of the 
most promising techniques. The third chapter describes the investigation of 
whether a wired pressure sensor in the bladder wall could be used to detect blad-
der onset in an acute animal model. The fourth chapter follows with corresponding 
chronic animal model experiments. The fifth chapter describes analysis and design 
of a passive wireless implantable pressure sensor. Finally, the thesis is concluded 
with a chapter containing a discussion of the obtained results, future perspectives 
of the research, and summarizing remarks. 
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I-2 The Lower Urinary Tract 
I-2.1 Anatomy 
The urinary tract consists of the kidneys, ureters, bladder and outlet. The kidneys 
produce droplets of urine, which are led by the ureters down and into the bladder. 
The role of the bladder is low pressure storage and periodical release of the urine. 
The outlet consists of the urethra, and the internal and external sphincters. The 
sphincters, together with the smooth muscle of the urethra, functions to open or 
close the outlet as desired. The kidneys and ureters are referred to as the upper 
urinary tract (UUT), while the bladder and the outlet is termed the lower urinary 
tract (LUT). The anatomical details of the UUT are outside the scope of this thesis. 
The anatomy of the LUT is illustrated in Figure 1. 
The bladder consists of three layers. The inner layer is the urothelium, which is a 
specially adapted epithelium lining the inside of the bladder. The middle layer of 
the bladder consists of smooth muscle, and is termed the detrusor. The outer layer 
is a fascia termed the serous coat. The outlet consists of the urethra, the internal 
urethral sphincter (IUS) and the external urethral sphincter (EUS). The IUS is placed 
 
Figure 1: Anatomy of the Lower Urinary Tract (LUT). 
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at the junction between the bladder and the urethra, while the EUS is placed more 
distal at the same level as the pelvic floor. The pelvic floor musculature is not part 
of the urinary tract, but supports the LUT, and can work synergistically with the 
sphincters to maintain continence.  
I-2.2 Neuroanatomy and physiology 
Peripheral innervation of the bladder originates from the thoracic, lumbar and 
sacral segments of the spinal cord. Anatomically, the bladder and urethra are vis-
ceral organs, and are innervated by branches of the autonomous nervous system. 
The external urethral sphincter (EUS), however, is under direct voluntary control 
and is innervated by somatic fibers. 
Overview 
The LUT has 2 functions, storage and periodical elimination of urine. These two are 
mutually exclusive; the system works in an on-off fashion. During storage, afferent 
sensory information about bladder distension is conveyed to the CNS as the blad-
der fills. At some critical point, the input becomes so strong that reflex voiding 
occurs. During normal voiding, positive feedback from flow-receptors in the urethra 
act to augment the bladder contraction to ensure complete emptying of the blad-
der with no post-void residual urine. When voluntary control of micturition is 
learned, tonic input from higher brain centers act to suppress the reflex, until at 
some point this is no longer possible, or voiding is initiated voluntarily.  
Efferent innervation of the LUT 
The detrusor is commonly said to be innervated by the hypogastric nerve, and the 
pelvic nerve. The hypogastric nerve is a sympathetic nerve originating at the T10-L2 
level of the spinal cord. Fibers run from the spinal cord, through the inferior mes-
enteric plexus, and either via the hypogastric nerve trunk to the bladder dome, or 
through the pelvic plexus to the bladder base and urethra [10, 11]. The fibers are 
active in the storage phase; their mechanism of action is the release of Nor-
Epinephrine (NE), which binds to β3-adrenergic receptors of the detrusor, causing 
the detrusor to relax, and which binds to α1-receptors in the urethra, causing con-
traction. The pelvic nerve is a parasympathetic nerve originating at the S2-S4 level of 
the cord; the fibers run through ganglia in the pelvic plexus, or in the bladder wall. 
Post-ganglionic fibers originating these two places constitute the parasympathetic 
innervation of the bladder. They act by releasing Acetyl-Choline (ACh) that binds to 
M3-receptors, causing detrusor contraction. The urethra is also innervated by para-
sympathetic fibers; they cause relaxation by releasing nitric oxide (NO). Thus, alt-
hough it simplifies the matter, strictly speaking one cannot say the bladder is inner-
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vated by the hypogastric or the pelvic nerve, but by sympathetic and parasympa-
thetic fibers running in these nerve trunks, at least part of the way. 
Contrary to the rest of the LUT, which is under autonomic control, the EUS is inner-
vated by somatic fibers. They originate at the S2-S4 level of the spinal cord, and run 
via the pudendal nerve to the EUS. They act by releasing ACh that binds to nicotinic 
receptors, causing contraction. A schematic view of the neuroanatomy of the LUT is 
shown in Figure 2. 
In healthy persons, the storage phase is characterized by synergistic activity of 
hypogastric nerve fibers to relax the detrusor muscle and hypogastric and pudendal 
nerve fibers to contract the sphincters. This ensures low pressure continent stor-
age. In the voiding phase of the micturition cycle, efferent activity in these nerves 
ceases, and the efferent fibers of the pelvic nerve become active, causing detrusor 
contraction. This is summarized in Table 1. 
Afferent innervation of the LUT 
Sensory afferent fibers run in all three nerves (hypogastric, pelvic, pudendal). Sen-
sory Aδ-fibers originating from the bladder wall relay wall distention information to 
the CNS. These fibers run mainly in the pelvic nerve, but also in the hypogastric 
nerve [10, 12]. In addition, C-fibers carry information about noxious or chemical 
Table 1: Schematic representation of the efferent nerve activity and corresponding action 
during storage and voiding. Nerves that are shown in light grey are inactive. EUS: External 
Urethral Sphincter; IUS: Internal Urethral Sphincter; ACh: Acetyl-Choline; NE: Nor-Epinephrine; 
NO: Nitric Oxide; N: Nicotinic receptor. 
 Part of Nervous 
System 
Nerve Level of 
origin 
End organ Neuro- 
transmitter 
Recep-
tor 
Function 
St
o
ra
ge
 
Somatic Pudendal nerve S2-S4 EUS ACh N Contraction 
Sympathetic Hypogastric nerve T10-L2 Detrusor 
Urethra/IUS 
NE 
NE 
β3 
α1 
Relaxation 
Contraction 
Parasympathetic Pelvic nerve S2-S4 Detrusor    
V
o
id
in
g 
Somatic Pudendal nerve S2-S4 EUS    
Sympathetic Hypogastric nerve T10-L2 Detrusor 
Urethra/IUS 
   
Parasympathetic Pelvic nerve S2-S4 Detrusor 
Urethra 
ACh 
NO 
M3 Contraction 
Relaxation 
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stimuli [13]. Since they do not respond to distention, these fibers are called ‘silent 
C-fibers’ in healthy. The urothelium has been found also to play a role in the senso-
ry and signaling properties of the bladder. In the suburothelial layer, a network of 
sensory fibers was identified together with a layer of interstitial cells, dense at the 
bladder neck, and sparse at the bladder dome. Further, from the suburothelial 
neural network, terminal fibers were found to project into the urothelium. The 
urothelium, in turn, was found to contain both a range of different receptors, and 
the ability to release neurotransmitters such as ATP and ACh. It is believed, that the 
urothelium, the interstitial cells, afferent nerves and smooth muscle might collec-
tively act as the stretch-receptor organ of the bladder [12, 14, 15], although the 
precise mechanism of action is still not well established. 
Central centers involved in bladder control 
In voluntary voiding, the decision to void is believed to be made in the prefrontal 
cortex; the signaling probably also includes the anterior cingulate cortex, the thal-
amus, the hypothalamus, the basal ganglia and cerebellum [12]. Although several 
higher centers are involved, they merely control whether to store, or to void. The 
 
Figure 2. Innervation of the Lower Urinary Tract (LUT). From Ref. [1] with permission. 
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area believed to be responsible for the transition between the phases is the Peria-
queductal Grey (PAG). In the pons there is functional imaging evidence of two dis-
tinct centers: a lateral center commonly termed the Pontine Storage Center (PSC), 
and a medial center termed the Pontine Micturition Center (PMC). The role of the 
PSC is not clear; it might simply help to facilitate the storage ‘reflex’ by adding ex-
citatory input to the reflex loop. When the decision to void has been made, the 
PAG activates the PMC. This causes a sequence of actions. Firstly, an inhibitory 
effect on the pudendal nerve is asserted, causing the EUS to relax. Then, the activi-
ty of the hypogastric nerve is inhibited, simultaneously with excitatory input to the 
pelvic nerve. This causes the outlet to open, and the detrusor to contract. Flow 
receptors in the urethra activate an additional positive feedback spinal reflex arch, 
augmenting the detrusor contraction until the bladder has been completely emp-
tied. In the storage phase, tonic suppression of the PAG from the higher brain cen-
ters prevents activation of the PMC. When, at a socially acceptable time and place 
voiding is desired, this suppression is interrupted, and the PAG provides excitatory 
input to the PMC, initiating voiding and suppressing the storage reflex until the 
bladder is empty. 
I-3 Etiology and Pathophysiology of NDO 
Most of the time is spent in the storage phase; about 23 hours and 40 minutes each 
day. Consequently, disorders related to the storage phase have the largest impact 
on patients. As mentioned previously, NDO can be caused by SCI, MS, Parkinson’s 
disease and stroke [2]. It is also often present in patients with spina bifida [16]. 
Other diseases that are characterized by neural lesions or degeneration may also 
lead to NDO. Most patients with NDO also develop detrusor sphincter dyssynergia 
(DSD) [17-19]. DSD is the concurrent contraction of the detrusor and the sphincter, 
which causes high transient intravesical pressures. Despite the activation of the 
outlet, incontinence episodes may also occur. 
To patients, the symptom of incontinence episodes is detrimental to their quality of 
life [20]. Patients with cauda equina lesions often suffer from areflexive bladder; 
they prefer this condition to “normal” bladder function with incontinence episodes 
[21]. In fact, bladder and bowel function, and sexual function, are the ones priori-
tized the highest among patients with SCI, much more than e.g. walking [5]. From a 
clinical perspective, the high transient pressure and post-void residual urine are the 
main problems. They can cause recurrent urinary tract infection (UTI), vesico-
ureteral reflux, and ultimately renal failure [22-24]. Previously, renal failure was the 
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most frequent cause of death in patients with SCI; despite considerable improve-
ments in management it still ranks as the fourth most frequent cause of death [4]. 
In layman’s terms, NDO is the lack of control and coordination of the spinal reflex 
loops, due to nerve damage. However, the pathophysiology varies somewhat be-
tween the different conditions. In suprapontine lesions (e.g. Stroke, Parkinson’s 
disease), the tonic inhibition of the PAG, and hence the PMC, is destroyed. This 
results in decreased bladder capacity and NDO [2, 12]. 
After SCI the bladder initially becomes areflexive; this is followed by development 
of NDO. This type of neurogenic DO is mediated by the emergence of a capsaicin-
sensitive, C-fiber-mediated spinal micturition reflex due to reorganization of synap-
tic connections in the spinal cord [2, 25]. 
In patients with MS the neurological lesions may be either spinal or cerebral. Spinal 
lesions are the most common, but the emergence of a new reflex similar to SCI has 
not been shown. Instead, the demyelination of the spinal nerves may cause unco-
ordinated control. With cerebral lesions a pathophysiology similar to Stroke or PD 
may be expected.  
I-4 Prevalence and Incidence of NDO 
The prevalence of NDO among the general population was recently surveyed. It 
was concluded that “Neurologic dysfunction of the LUT occurs in many patients 
with neurologic disease but exact [prevalence] figures are seldom available.” [6] 
The most common causes of NDO are SCI and MS. Despite narrowing down to two 
diseases, exact prevalence figures do not exist. For SCI, prevalence estimates vary 
from 223–755 per million [26], with one study mentioning a range of 110-1120 per 
million [27]. Assuming a mean prevalence of SCI of 500 per million in the Western 
world, the number of SCI patients is approximately 400.000. Regarding MS, a 
worldwide prevalence of 1 million has been estimated [28]. 
It was shown that electrical stimulation of pudendal afferents caused bladder re-
laxation is both healthy and NDO patients. Thus, a neural prosthesis for treating 
NDO could also be used to treat non-neurogenic DO. This is one of the pathologies 
of OAB with Urinary Urgency Incontinence (UUI) in the general population.  
Looking at the broader OAB syndrome, two large studies have examined the preva-
lence. These are the NOBLE study [29], and the EPIC study [30]. Just before the 
2002 definition of OAB [1], another large scale study was published; the SIFO study 
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[31]. While overall prevalence of OAB cannot be compared between the SIFO study 
and the other two studies, prevalence for the sub-pathologies can. There is agree-
ment between all studies, that the overall prevalence of OAB is approximately 
16 %. Further, approximately 6 % of the population was found to have OAB with 
UUI, and approximately 10 % had OAB without UUI. It was reported that up to 90 % 
of patients with NDO become continent with antimuscarinics and catheterization 
[32]. If the same number applies to the general population, 0.6 % or 4.8 million in 
the EU and USA would still suffer from refractory OAB, and could potentially bene-
fit from a neural prosthesis. 
I-5 Management of NDO 
Treatment options for NDO include behavioral modification, pharmacological 
treatment, surgical treatment and neuromodulation. In stress urinary incontinence, 
physiotherapeutical training is a very effective treatment option [33], however, 
there is no evidence that this has any benefit in urgency incontinence patients [34]. 
I-5.1 Behavioral modification 
First line treatment is education and behavioral modification. This implies educat-
ing patients about bladder function and appropriate fluid intake. General guidelines 
for fluid intake are to avoid caffeine, to maintain adequate hydration throughout 
the day, and to time fluid intake according to daily routines. A regime of “Bladder 
training” would generally include patient education, scheduled voiding, urge-
suppression techniques and pelvic-muscle exercises. [35]. The value of the educa-
tional part alone has been hypothesized to underlie the marked placebo effect 
observed in drug trials (up to 30 % improvements in symptoms) [36]. 
I-5.2 Pharmacological treatment 
Antimuscarinics 
First line pharmacologic treatment of NDO is the administration of antimuscarinics 
(also known as anticholinergics). They are typically targeted at blocking the M2 or 
preferably the M3-receptors of the detrusor, thereby preventing or at least dimin-
ishing the strength of detrusor contractions [37]. 
A limiting factor of antimuscarinic treatment is that M3-receptors (and M1-M5-
receptors, to which the drugs also bind, albeit with a lower affinity) are found in 
other organs as well. Thus, common side-effects include dry mouth, constipation, 
gastroesophageal reflux, blurry vision, urinary retention and cognitive side effects. 
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[32, 36, 38]. While antimuscarinic treatment is adequate for some, many continue 
to have problems even after maximal therapy is applied [39]. 
There are several other drug classes under investigation, e.g. GABA-receptor ago-
nists, potassium channel openers [36] potassium channel blockers, calcium channel 
blockers and β-adrenoceptor agonists [40]. However, none of these are currently 
used in routine management of NDO. 
Capsaicin and Resiniferatoxin (RTX) 
Resiniferatoxin (RTX) is an analog of capsaicin; they belong to the group of sub-
stances known as vanilloids. Their mechanism of action is that they desensitize 
vanilloid receptors of unmyelinated sensory C-fibers. As described in section I-2.1, a 
C-fiber mediated micturition reflex arises in patients with spinal NDO. Administra-
tion of capsaicin or RTX, and the subsequent desensitization of the C-fibers, reduc-
es neural firing and inhibits the micturition reflex [41, 42]. Capsaicin was first used 
to treat NDO with success, despite acute pain and bladder irritation. RTX is more 
potent that capsaicin, and appears to share the efficacy of capsaicin albeit with less 
side effects [43].  
Botumlinum Toxin-A (BoNT-A) 
Botulinum toxin (BoNT) is a highly potent neurotoxin that blocks the release of 
neurotransmitters from nerve endings. This causes a prolonged period of paralysis, 
during which the affected nerve endings become inactive, and new endings sprout 
to re-innervate the affected organ [42, 44]. There are seven serotypes of botulinum 
toxin, named A to G that attain the same effect by different mechanisms. Serotype 
A (BoNT-A) is the most used for treatment of NDO. It acts by cleaving the SNAP25 
protein, which normally allows vesicles containing neurotransmitters to fuse with 
the membrane. Without SNAP25, the vesicles can no longer fuse with the cell 
membrane, and release of the transmitter substance is prevented [45]. The first 
larger study of BoNT-A as treatment for NDO was a European multicenter study 
with 200 participants [46]. Participants had BoNT-A injected into the detrusor, and 
after 3 months, mean volume at first reflex contraction and maximal capacity had 
both increased by more than 50 %, and 73 % of patients achieved full continence 
between catheterizations. The efficacy of BoNT-A was later confirmed by a ran-
domized, double-blind placebo-controlled study [47]. The treatment needs to be 
repeated at 6-9 month intervals, but repeated injections seems to be as effective as 
the first [48]. There has been raised concerns about the cost of treatment, the long 
term effects, and the risk of urinary retention [44, 49]. The latter, however, is most-
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ly relevant to patients with idiopathic DO; patients with NDO almost universally use 
a catheter to empty their bladder. 
I-5.3 Surgical Treatment 
Augmentation cystoplasty 
Augmentation cystoplasty is the surgical augmentation of the bladder. Usually, a 
patch of the sigmoid colon (sigmoidocystoplasty) or the ileum (ileocystoplasty) is 
used [50]. Such bowel patches are extremely compliant; the result is increased 
bladder capacity and low pressure storage. As a consequence, natural voiding be-
comes impossible, and a catheter must be used to empty the bladder. Due to high 
rates of complications, alternative methods (patches from other intestines or or-
gans, and the use of artificial materials) are under constant investigation [51]. 
Detrusor myectomy 
Detrusor myectomy is based on a somewhat similar principle. Instead of augment-
ing the bladder with a patch of bowel, part of the detrusor muscle is removed. The 
remaining urothelium is, similar to a bowel patch, very compliant, and the proce-
dure results in increased capacity and low pressure storage, with the need for 
catheterization to empty. The efficacy of the procedure is not as high as for aug-
mentation cystoplasty, however, complication rates are lower [52, 53]. 
 
I-5.4 Neuromodulation 
Neuromodulation has the potential of becoming a preferred treatment modality 
for patients with NDO. Currently, however, there are only two systems available in 
the clinic. The first, and the only approved treatment option for NDO, is the Fine-
tech-Brindley bladder system. The second is the InterStim system, which is ap-
proved for UUI, and used experimentally in patients with NDO. However, the sys-
tem is not yet approved, and as of 2004 was implanted only in 83 patients [54]. 
Neuromodulation requires the implantation of at least a pulse generator (stimula-
tor) and an electrode. A system as proposed in this thesis also requires the implan-
tation of a sensor. Even with minimally invasive surgery, this may seem radical 
compared to pharmacological treatment. However, there are two arguments why 
neuromodulation may still be an attractive alternative to drugs. The first is the 
efficacy. Upon successful initial screening of the patient, most patients have higher 
rates of symptom relief using neuromodulation that pharmacological treatment. In 
addition, there are also fewer side effects. The other is more of a societal than a 
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patient concern; it relates to the cost of treatment. For the specific case of the 
Finetech-Brindley Bladder system, it was found that the break-even time between 
the initial cost of the device and the implantation procedure, and the cost contin-
ued conventional treatment, was 5 years [9]. 
Because of the potential benefits, a range of different systems have been proposed 
in the research literature. On the other hand, bringing a neuroprosthesis to market 
is expected to cost 80-100 million US dollars, and the research part is expected to 
take 5-7 years. Thus a considerable investment must be made, even beyond large 
research grants, for this to happen. This may be one of the obstacles for breaking 
the barrier between research and commercial systems.  
 
Interstim 
The most widely used neuroprosthesis for restoring continence is the Medtronic 
Interstim. It is used to treat urgency incontinence, but also urgency-frequency in-
continence, urinary retention and fecal incontinence. The therapy is based on sa-
cral root stimulation; a quadripolar electrode is placed in the S3 foramen, and 
stimulation is applied continuously below sensory threshold. Clinical trials started 
in 1993, CE-marking was obtained in 1994, and FDA approval for treating urgency 
incontinence was obtained in 1997 [55]. The use of Interstim therapy has increased 
exponentially; the 10.000 implant milestone was reached in 2004 [54], in 2011 
implant number 100.000 was celebrated. 
Both screening and implant technique has improved significantly since the intro-
duction [56]. Initially a so-called percutaneous nerve evaluation (PNE) was per-
formed to assess the efficacy of treatment. This consisted of the placement of a 
percutaneous temporary lead at the S3 forarmen close to the S3 root. This lead was 
connected to an external stimulator where stimulation parameters could be ad-
justed. This was followed by a 3 to 7 day testing period; at baseline and during this 
testing period the user kept a voiding diary, to document any effect. Patients with a 
documented 50 % or higher reduction in at least one symptom would get the Inter-
stim system implanted. With this technique, a 3 year follow-up showed that 59 % 
of patients reported a 50 % or larger decrease in symptoms, and 46 % reported 
turning completely dry [55]. However, an average of 5.0 ± 6.1 leaks per day was still 
reported, and only around 50 % of patients had a successful PNE.  
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The evaluation scheme has changed to what is called a two-stage implant. In this 
scheme, the permanent quadripolar tined lead is implanted, and connected to a 
percutaneous extension cable. This cable is connected to an external stimulator. 
This avoids any problems of lead migration, and allows for a prolonged evaluation 
period. Follow-up studies showed that 80-90 % had at least a 50 % symptom reduc-
tion [57-59]; leakage episodes decreased from average 9.5 to 3.3 [58]. 
In light of the efficacy and popularity, it is paradoxical that the same implant is used 
to treat both urinary incontinence and urinary retention. In fact, the mechanism of 
action is not at all clear [60]. Different stimulation parameters are typically used for 
the different conditions, and current hypotheses evolve around this. Some parame-
ter sets might cause direct action (neurostimulation) while other parameters 
modulate reflex activity (neuromodulation). A better understanding of the neuro-
physiology of the LUT, combined with improved functional imaging techniques, 
may lead to an understanding [60].  
 
SARS/SPARSI (Finetech-Brindley Bladder System) 
The only neuroprosthesis to become widespread for the treatment of NDO was the 
Sacral Anterior Root Stimulator (SARS), also known as the Finetech-Brindley Blad-
der System. The first implants were performed in 1978, and by 2004 more than 
2.500 implants were performed [54]. It is a system to restore voiding, it does not by 
itself inhibit involuntary detrusor contractions. In order abolish involuntary con-
tractions the sacral posterior roots are cut, a procedure known as a posterior rhi-
zotomy [Brindley1986]. This renders the bladder areflexive, but also causes loss of 
reflex defecation and erection if present. For voiding, the system takes advantage 
of the differences in smooth and striated muscle tissue properties. When stimula-
tion is on, contraction of both the detrusor and the external sphincter occur. When 
stimulation is turned off, the striated sphincter relaxes instantaneously, whereas 
the smooth detrusor muscle fibers keep tension for a considerable period of time. 
This results in urine flow, as long as the intravesical pressure is larger than the ure-
thral pressure. Once the flow stops, another stimulus bout is given. This results in a 
pattern called post-stimulus voiding, and while not very  similar to physiological 
voiding, residual volumes of less than 30 ml are generally possible [61]. 
The loss of reflex erection and defecation (if present) due to the posterior rhizoto-
my has been the primary limiting factor for the acceptance of the system. In order 
to accommodate this, the system was configured as a Sacral Posterior Anterior 
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Root Stimulator Implant (SPARSI) [62]. In addition to the traditional SARS configura-
tion, a lead for stimulating the posterior roots is included. This was evaluated in 
five patients with complete SCI. All 5 retained reflex erection after the implant, and 
3 had persistent NDO. Continuous stimulation was applied to the posterior roots in 
these 3 patients, and this was remarkably effective; bladder capacity more than 
doubled in two of three patients. High pressures (> 70 cmH2O) could still be gener-
ated for voiding, but persistent DSD prevented complete emptying. The mechanism 
of action of the posterior root stimulation expected to be similar to that of Inter-
stim therapy. 
 
The Bion 
The Bion is a wireless injectable microstimulator. Several versions exist; they are 
similar in that they consist of a small glass cylinder (the first version was 2 mm in 
diameter and 10 mm in length), with coils and electronics in the cavity, and an 
electrode at each end. It was described by Loeb et al. in 1991 [63], and has been 
used for various applications such as pressure ulcer prevention, knee osteoarthritis, 
and correction of foot drop, shoulder subluxation and post-stroke hand contrac-
tures [64]. For treatment of NDO a larger version was used. It measured 3.3 mm in 
diameter and 27 mm in length, and was implanted in Alcock’s canal adjacent to the 
pudendal nerve. Stimulation was applied continuously, at a 50 % duty cycle (5 s on, 
5 s off). 
One study included 14 women, who underwent a percutaneous screening test 
(PST). A cystometrogram was performed at baseline, the patients received stimula-
tion for 10 min, and if they showed at least 50 % increase in either volume at first 
involuntary contraction, or maximum cystometric capacity, they received the im-
plant. 6 women had a positive PST. At 6 months follow-up, they all had improved in 
incontinence episodes; the average decrease was from 6.2 ± 2.5 to 2.4 ± 2.1 incon-
tinence episodes a day. Similarly had the pad usage decreased from on average 
5.2 ± 2.7 a day to 2.8 ± 2.1 [65]. Another study included only 2 women, one with 
UUI and one with frequency. Both passed the PST, and received the implant. At 1 
month follow-up, the first had a reduction in number of incontinence episodes of 
31 %; the other lowered her voiding frequency from 12 to 7 times a day [66]. These 
small studies suggest an efficacy similar to the Interstim therapy, however larger, 
long term trials are required to verify this. The Bion has received the European CE 
mark for use in treating UUI. 
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Miniaturo 
The Miniaturo is an electrostimulator with the stimulation lead placed paraure-
thrally. The implant works by stimulating the EUS, thereby activating an inhibitory 
reflex as described by Shafik [67]. It delivers continuous stimulation “with an inter-
rupted cycle of 16 s every 5 s (15 s pause)” [68]. An initial study on the efficacy in 
treating OAB included 7 women with refractory OAB manifested by both frequency 
of more than 10 a day and urgency incontinence. At 12 months follow-up all meas-
ured parameters had improved; frequency decreased from median 15.2 a day to 
9.4 a day, and incontinence episodes decreased from 9.1 to 1.8. One woman had to 
have the implant removed after 10 months due to infection at the implant site [68]. 
The Miniaturo received the CE mark as treatment modality for interstitial cystitis 
(IC) and OAB in 2005 [69]. 
 
PTNS 
Another option for treating NDO is to apply therapeutic percutaneous tibial nerve 
stimulation (PTNS). A small needle electrode is inserted near the ankle to stimulate 
the tibial nerve. Stimulation is continuous at 20 Hz, with current levels of 0.5 to 9 
mA. Treatment consisted of weekly sessions of 30 min each for 13 weeks. PTNS was 
compared to validated sham stimulation [70]. A total of 220 patients were enrolled 
in the study, 110 in each group (PTNS vs. Sham). In the PTNS group, 54.5 % indicat-
ed moderate or marked improvements in symptoms, compared to 20.9 % in the 
sham group [71]. It was later shown, that the effect could be maintained by one 30 
min session every fourth week [72]. 
 
I-6 Conditional stimulation to treat NDO 
All currently accepted treatment options use continuous, intermittent (based on 
therapeutic carry-over effects) or manually triggered stimulation. As described in 
the previous section, they all improve symptoms, but they do not effectively cure 
the condition. It has been shown that genital nerve stimulation can suppress nas-
cent bladder contractions [73-77]. Conditional stimulation also increases the maxi-
mum cystometric capacity compared to continuous stimulation [78]. 
A system intended to completely treat symptoms of NDO based on conditional 
stimulation has been proposed [Hansen2005]. The described system consists of 
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external equipment, and is based on a pressure sensor, a control unit, and a stimu-
lator connected to surface electrodes placed above the dorsal penile or clitoral 
nerve. The system works by continuously analyzing the pressure signal, and once 
an involuntary contraction is detected, stimulation is applied, causing the bladder 
to relax. At the same time, the patient is warned that he or she should consider 
emptying the bladder as soon as convenient. 
The system was evaluated in 16 patients with SCI during a filling cystometrogram 
session. 13 responded to stimulation, and had at least one involuntary contraction 
suppressed (mean ± SD was 16 ± 17). Maximum cystometric capacity improved in 
all patients, on average by 53 %. On average, there was 20 min from the first sup-
pressed contraction, until leakage occurred. Assuming that patients empty their 
bladder during this period, they would become symptom free. 
The missing component in making such an implantable system is an implantable 
sensor capable of detecting the onset of bladder contractions in a chronic setting. 
Several sensors have been proposed, as reviewed in the next chapter. The work 
described in the remainder of this thesis relates to the development of an implant-
able pressure sensor intended to be placed in the bladder wall. 
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Abstract 
This study investigated whether signals, obtained from a pressure sensor chronical-
ly implanted in the urinary bladder wall of pigs, could be used to detect the onset 
of bladder contractions. The sensor was encapsulated with a thin layer of silicone; 
it was lens shaped with a diameter of 13.6 mm and height of 2.0 mm. Experiments 
were performed in 5 pigs with duration from 4 weeks to 3 months. Sensors were 
either fully implanted for 3 months (n=2) or the leads were left transcutaneously to 
enable weekly follow-up experiments for 4 weeks (n=3). For follow-up, pigs were 
mildly sedated with propofol, after which a double-lumen transurethral catheter 
was placed for reference measurement of the intravesical pressure, and for artifi-
cial filling. Contraction evoked by filling distention occurred in one pig; the signals 
obtained from the implanted sensor in this pig could be used to detect the onset of 
contraction. In the other pigs, it was not possible to obtain contractions. The 
propofol anesthetic, a too low filling volume and a too slow filling rate may all have 
contributed to this. In the transcutaneous group, 4 of 6 sensors were in place at the 
time of termination; in the fully implanted group none of the 4 sensors were in 
place. This success rate needs to be improved for the application to become feasi-
ble.  
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IV-1 Introduction 
Neurogenic detrusor overactivity (NDO) is a diagnosis characterized by involuntary 
bladder contractions at low intravesical volumes. NDO is generally caused by neu-
rological lesions related to spinal cord injury, multiple sclerosis, Parkinson’s disease 
or similar conditions [1]. In addition to NDO, most patients also develop detrusor-
sphincter-dyssynergia, which is the concurrent contraction of the detrusor and the 
urethral sphincter. Despite this antagonistic action, involuntary detrusor contrac-
tions often lead to incontinence episodes. From a patient perspective, incontinence 
episodes are embarrassing, and have a detrimental impact on the quality of life [2]. 
However, from a clinical perspective the high transient pressure during concomi-
tant contractions is of more importance, since it can lead to vesicouretral reflux 
and ultimately renal damage [3]. 
One treatment modality for NDO is to apply electrical stimulation to the dorsal 
genital nerve (DGN), as this is able to suppress bladder contractions. Stimulation 
can be applied both continuously and conditionally [4-6]. Continuous stimulation is 
able to suppress contractions until a certain intravesical volume is reached. At this 
critical point, stimulation no longer has any effect. The disadvantage of continuous 
stimulation is primarily that the patients do not know how close to maximal capaci-
ty they are, and thus when stimulation will cease to show an inhibitory effect. In 
addition, stimulation may cause an unpleasant sensation, and habituation of the 
reflex loop may occur over time, limiting or even abolishing the effect of stimula-
tion. Conditional stimulation is a scheme where stimulation is applied at the onset 
of an involuntary bladder contraction, thereby abolishing the contraction before 
the intravesical pressure reaches a pathologic level. Such conditional stimulation 
requires a sensor capable of detecting the onset of bladder contractions, but it 
offers several advantages compared to continuous stimulation. The most important 
advantage is that an estimation of bladder fullness is obtained. Involuntary contrac-
tions occur more and more frequently as intravesical volume increases [7]. Typical-
ly, contractions can be suppressed for at least 30 minutes from the first contraction 
[8], providing the patient time to empty his bladder in a controlled manner. Thus, 
high transient pressures can be avoided altogether. Previously, chronic implanta-
tion of pressure sensors has been studied [9], but only the implant stability was 
evaluated. The ability of such implanted sensors to detect the onset of bladder 
contractions was never assessed. Recently, a sensor for detecting the onset of 
bladder contractions was developed and tested in acute animal experiments [10]. 
The objective of this study was to investigate whether it was possible to detect the 
onset of detrusor contractions using pressure sensors implanted chronically in the 
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bladder wall for periods of up to 3 months. As a secondary outcome measure the 
number of eroded sensors and the state of the remaining sensors during this peri-
od were also reported. 
IV-2 Methods 
IV-2.1 Outline and protocol 
All experimental procedures were approved by the Danish Animal Welfare Commit-
tee. Chronic experiments were performed in minipigs to obtain both intravesical 
pressure and pressure in the bladder wall simultaneously during bladder contrac-
tions evoked by artificial filling of the bladder. The experimental series consisted of 
one pilot experiment and additional four experiments. In the pilot experiment, two 
pressure sensors were implanted in bilateral aspects of the bladder wall near the 
bladder dome. The wires from one sensor were tunneled to the back of the pig and 
brought through the skin. Wires from the other sensor were placed in a pouch 
between the abdominal cavity and the skin. In the four additional experiments, two 
pigs had the wires from one sensor similarly tunneled to the back and through the 
skin, the other two had the sensors and wires completely implanted. 
Weekly follow-up experiments were conducted in the pigs with transcutaneous 
leads for a period of four weeks. They were anesthetized and put to the operating 
table, where the impedances of the sensors were measured to indicate proper 
electrical functioning of the sensors. Then a transurethral double-lumen catheter 
was placed in the bladder; this was used for artificial filling and measurement of 
intravesical pressure using an external sensor. Contractions were evoked (if possi-
ble) by the artificial filling, and bladder pressure was recorded during the entire 
filling session. The two pigs with sensors completely implanted were put in their 
booths for 3 months before a terminal experiment.  
Identical terminal experiments were conducted in all animals, similar to the acute 
experiments described in an earlier study [10]. In brief, the pelvic nerve was ac-
cessed by a posterior approach as described by Wen et al. [11], and a cuff electrode 
was placed unilaterally to evoke hemispheric bladder contractions by electrical 
stimulation. Intravesical pressure, measured by an external sensor via a tran-
surethral catheter, and pressure in the bladder wall was recorded simultaneously. 
IV-2.2 Animal Model 
The study was performed on five Göttingen minipigs weighing 30 to 40 kg. Due to 
difficulties evoking bladder contractions, two anesthetic schemes were used. In 
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scheme one induction consisted of Ketamine (15 mg/kg), Stresnil (2.2 mg/kg) and 
Atropine (0.04 mg/kg) given I.M. as a bolus injection. The pig was intubated and 
ventilated, and anesthesia was maintained with Propofol i.v. (6 ml initial bolus, 10-
14 ml/h following) (“Propofol scheme”).  
In the second scheme induction consisted of Ketamine (10 mg/kg) and Midazolam 
(1 mg/kg) given I.M. as a bolus. The pig was subsequently intubated and ventilated, 
and anesthesia was maintained using Sevoflurane (1–1.5% vol) (“Sevoflurane 
scheme”). 
For implantation a mixture of Zoletil, Rompun, Ketaminol and Turbogesic was used; 
for details see [10]. Heart rate and oxygen saturation was monitored in all experi-
ments. The experiments were approved by the local ethical committee. 
IV-2.3 Sensor and Equipment 
The sensor itself and the silicone encapsulation of the sensor was identical to what 
is described in an earlier study [10]. Compared with the described sensor, the wires 
were changed to small single-lead Teflon-coated MP35N wires (Fort Wayne Metals, 
Fort Wayne, IN; Wire specification: 1x19 strand, FEP coated, outer diameter 0.3 
mm). With the choice of sensor, the MP35N could not we welded on the soldering 
pad, as the temperature required destroyed the pads. Instead, a small piece of 
copper wire was welded on the end of each of the four leads, and this small piece 
of copper was soldered to the pads. The copper was completely covered with the 
soldering tin, except for one case where this was not possible. To relieve stress 
from the solders and welds, a simple mechanism was used. A small silicone cylinder 
was placed adjacent to the sensor transversal to the direction of the wires, and a 
knot was tied around it with each wire. This cylinder with the knots of all four leads 
was then encapsulated together with the sensor, as illustrated in Figure 3. After 
moulding, dip-coating was done twice with a low-viscosity dip-coat solution (28 g 
heptane to 35 g silicone (NuSIL, Carpinteria, CA; MED 1137)), to fill any creases 
especially around the wire exits. 
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A continuous infusion pump (Carefusion, San Diego, CA; IVAC 598) was used for 
artificial filling at a rate of 999 ml/hour (pump max), corresponding to 16.7 ml/min. 
Maximum infused volume was set to 400 ml. If contractions did not occur at this 
point, a second filling was attempted. If still no response was obtained, the rec-
ording session was terminated. The rest of the setup was described in a previous 
study [10], it is repeated below for clarity. 
Intravesical pressure was used as reference signal. This was measured through a 
transurethral catheter (Medtronic Functional Diagnostics A/S, Skovlunde, DK; 2-
way Catheter, 10 Fr., 400 mm) using an external pressure transducer (Edwards 
Lifesciences, Irvine, CA; TruWave PX600F, relative-type transducer). 
Both the implanted sensor and the reference sensor are full-bridge sensors. Using 
custom made connectors they were connected to an amplifier (Molecular Devices, 
Sunnyvale, CA; Axon CyberAmp 380) that also provided a +5.000 V precision output 
to drive the sensors. Data acquisition was done with a USB acquisition box (Nation-
  
(a) Moulded bottom part (b) Bottom cut to make 
space for cylinder 
  
(c) Knots for wire tension 
relief 
(d) Final sensor 
Figure 3: (a)-(d) The steps for modifying the moulding process to include a wire tension 
relief mechanism The thread knot on figure (c) was only used to keep the four wires to-
gether during handling, it was removed before the final moulding. 
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al Instruments, Austin, TX, Model NI USB-6009) controlled by custom software 
written in Matlab. The signals were amplified (2000x for the implantable; 500x for 
the reference sensor), lowpass filtered at 10 Hz (amplifier built-in 4th order Bessel 
filters), and sampled at 100 Hz. For offline viewing, a 2nd order Butterworth lowpass 
filter with a cutoff frequency of 0.5 Hz was applied digitally. 
IV-2.4 Surgical Procedure 
With the pig in the prone position, a transurethral catheter was placed in the blad-
der. A midline incision was made to expose the bladder. Using a syringe, urine was 
removed or saline was infused in the bladder to obtain a volume of approximately 
200 ml. Two pouches were made in the middle of the detrusor, one on each lateral 
aspect of the bladder near the bladder dome. Sensors were placed in the pouches, 
and the pouches were closed using a string purse suture. Wires from one sensor 
were cut at lengths 12, 13, 14 and 15 cm, to be able to distinguish between them, 
and placed uncoiled in a subcutaneous pouch. Wires from the other sensor were 
tunneled to the back of the pig, where they were simply left transcutaneously 
through small incisions. Finally a two-layered closure of the midline incision was 
done, one layer being the peritoneum, second layer the abdominal muscles and the 
skin. All pigs were treated with Gentamycin post implant. 
IV-3 Results 
In the pilot experiment, bladder contractions were evoked by artificial filling under 
the propofol anesthetic scheme. After 2 week experiment duration, a good record-
ing of a contraction was made; this recording is shown in Figure 4. After experiment 
durations of 3 and 4 weeks, reliable signals could no longer be obtained from the 
implanted sensor. In the remaining experiments bladder contractions could not be 
evoked. On occasion the pigs were brought out of anesthesia with a full bladder, 
and it was observed that they voided immediately after waking up. In total, 12 
filling experiments were made. Only the first four were successful in the sense that 
distention evoked contractions occurred. After another four unsuccessful experi-
ments using the propofol scheme, the sevoflurane scheme was used. Using this 
scheme we also failed to generate any contractions. 
In the one good recording that was made, the automatic detection algorithm pre-
viously described [10] was applied, and detection occurred in both traces without 
false positives. Onset was detected after 849.4 s using the intravesical pressure 
signal, and after 851.3 s using the wall pressure signal; detection using the wall 
signal was delayed by 1.9 s compared to the intravesical pressure. Intravesical pres-
sure at the time of detection was 11.7 and 12.7 cmH2O for the intravesical and wall 
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signal, respectively. Bladder compliance was 37 ml/cmH2O in the recording ob-
tained. 
 
 
Figure 4 Recording of one successful filling experiment. Top trace is the bladder wall pres-
sure, bottom trace is intravesical pressure. The straight line is the infused volume, according 
to the scale on the right-hand side of the graph. Crosses mark the points of onset detection 
by the automatic detection algorithm. 
 
Upon termination of the experiments, all bladders were dissected out and fixed 
with formalin. In the relaxed fixed state, bladder wall thickness was approximately 
9 mm on the ventral aspect, and approximately 5 mm on the dorsal aspect, with 
thickness decreasing uniformly from the ventral aspect to the dorsal. The urotheli-
um was found to constitute approximately one third of the wall thickness. Capsule 
formation was clearly seen around all sensors; thickness of this capsule was ap-
proximately 1 mm. With the very limited recorded pressure data at hand, it was not 
possible to assess the influence this capsule had on the sensitivity of the pressure 
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sensors. In addition to the capsule, an increase in urothelial thickness below the 
sensors was observed. These findings are illustrated in Figure 5. 
 
   
(a) (b) (c) 
Figure 5 Illustration of bladder wall thickness and capsule formation. (a) shows the wall 
thickness of the ventral aspect of the bladder. One cut was made at the ventral midline, and 
the bladder was held ‘open’ by sutures. Wall thickness was measured to 9 mm. (b) shows 
the thickness of the dorsal aspect of the bladder, by extending the cut. Here, wall thickness 
was measured to 5 mm. (c) illustrates the thickness of the connective tissue encapsulating 
the implanted sensor, the thickness of the connective tissue was approximately 1 mm. 
 
In several experiments large rhythmic pressure increases were seen in the bladder 
wall pressure signal for periods of 50 to 200 s. This occurred with bladder volumes 
ranging from an estimated 200 ml to 400 ml. Figure 6 shows an example of this. In 
the figure, the “magnified intravesical” pressure is obtained by multiplication and 
level shift; parameters were chosen manually for illustrating the similarity. 
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Figure 6 Slow rhythmic pressure increases observed particularly pronounced in experiment 
3. 
The transcutaneous lead-out did not cause any infection, nor was it observed to 
annoy the pigs. Four wires in total were led out at 2 different positions (2 power 
leads at one position, 2 signal leads at another). Impedance of the sensors (Wheat-
stone bridge topology) was checked before all experiments, and did not change 
over the cause of any of the experiments. Since pressure measurements were inac-
curate and inconsistent, despite good impedance measurements, impedance 
measurements could not be used to verify proper functioning of the sensors. The 
simple method of wire stress relief worked well; no leads broke, and no leads de-
tached from the soldering pads. 
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In the experiments with transcutaneous leads, 4 of 6 sensors stayed in place. The 
two sensors that eroded out of the bladder both had short wires placed in a subcu-
taneous pouch. In one of the two experiments with sensors completely implanted 
(i.e., without transcutaneous leads), both sensors had eroded out of the bladder 
wall. In the other, one sensor had eroded out of the bladder wall, the other had 
eroded into the bladder lumen. The sensor recovered from the pilot experiment 
was severely corroded, whereas the rest only showed minor signs of beginning 
corrosion. These findings are summarized in Table 2. 
 
IV-4 Discussion 
The aim of this study was to evaluate in a chronic setting, whether signals obtained 
from sensors implanted in the bladder wall could be used to detect the onset of 
detrusor contractions. The experimental series were only partly successful. In 4 of 5 
pigs, it was not possible to evoke contractions by artificial filling; in addition reliable 
signals could only be obtained from the sensors the first 2-3 weeks after implanta-
tion. 
A similar animal model was used by Greenland and Brading [12]. Landrace pigs 
were sedated with propofol at rates of 2 to 8 mg/kg/h, and bladders were filled 
with warm saline at a rates of 20 to 110 ml/min; predominantly 50 ml/min. For 
propofol infusion rates less than or equal to 4 mg/kg/h, there was no effect on the 
cystometrogram compared to non-sedated animals. At rates of 6 mg/kg/h or more, 
the bladders showed low compliance. They did not state a maximal infused volume 
in their paper; however, in the low-compliance example they showed that an in-
Table 2 Position of recovered sensors and their level of corrosion. None of the eroded 
sensors were recovered; hence their corrosion level could not be assessed. This is noted 
n/a in the table. 
  Position  Corrosion 
#  1st sensor 2nd sensor  1st sensor 2nd sensor 
1 Pilot study in place eroded  severe n/a 
2 1st w/leads out in place in place  minor minor 
3 2nd w/leads out in place eroded  minor n/a 
4 1st fully implanted inside bladder eroded  minor n/a 
5 2nd fully implanted eroded eroded  n/a n/a 
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fused volume of 550 ml was necessary before contraction. In the normal compli-
ance example only half of this, 225 ml, was necessary. Regarding the infused vol-
umes, it is relevant to note that the pigs they used were larger, weight range 58 to 
95 kg. 
Propofol infusion rates of 2.5 to 4.7 mg/kg/h was used in this study. This lies mostly 
within the ‘normal compliance’ range suggested. Despite this, the compliance in 
the one recording obtained in this study was only 37 ml/cmH2O. For comparison, in 
the study of Greenland and Brading, mean compliance was 620 ± 160 ml/cmH2O in 
the ‘normal’ case, and 58.7 ± 5.8 ml/cmH2O in the ‘low compliance’ case. In the 
low-compliance cases, contractions were still reported, although at higher intraves-
ical volumes. From the above it can be inferred that propofol has an inhibiting ef-
fect on the voiding reflex, and based on the very low compliance measured in this 
study, one could speculate that minipigs are more sensitive to propofol than land-
race pigs. However, in the last unsuccessful experiments using the propofol 
scheme, infusion rates were kept at an absolute minimum, eliminating the option 
of further lowering the infusion rate. The filling rate used in this study (16.7 
ml/min) was much lower than reported by Greenland and Brading, but it was the 
maximum rate of the available pump. A faster filling rate might produce increased 
afferent firing, increasing the change of triggering the voiding reflex. Also, a larger 
maximal infused volume could be used, if it could be asserted that it would not 
overdistend the bladder tissue. Altogether, the propofol infusion rate, the low 
bladder filling rate and the set maximum infused bladder volume may all collective-
ly have prevented the evoked contractions. Different provocative maneuvers are 
suggested for human urodynamic studies, e.g. infusion of ice water. This was not 
attempted in the pigs, but could be an option for future studies. 
One proper contraction was recorded in the pilot experiment, shown in Figure 4. 
The increase in pressure perceived by the implanted sensor at around 250-300 s 
may well be the unfolding of the bladder. At low volumes the bladder wall collaps-
es into rugae. When it fills, the rugae first unfolds, and after this, the bladder wall 
starts to stretch. This transition is likely what is seen at 250-350 s, where the initial 
stretching of the bladder wall around the sensor will yield a “static” pressure in-
crease. 
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As seen in Figure 4, there is a large amount of background noise in the recorded 
signals. This is primarily generated by the ventilator, and the infusion pump. Figure 
7 shows this at a smaller time scale. The 3-4 cmH2O pressure increases seen from 
1250 to 1265 are pressure increases of the entire abdominal cavity caused by the 
ventilator. At 1265 the infusion pump was turned on, adding to the signal a low-
frequent noise (approximately 1.8 Hz) with an amplitude of 2 to 3 cmH2O. It is also 
seen that the noise level of the implanted sensor is larger than that of the external 
sensor. Some of the noise could arise from the smaller sensitivity of the implanted 
sensor compared to the external sensor (amplification was 2000x and 500x, respec-
tively). 
It was also observed, that the noise level of the implanted sensor was larger when 
implanted, than in the lab. During manufacture and storage, the sensors were kept 
dry. Only during testing and calibration were they submerged. Tests were per-
formed using vials of demineralized water, for two reasons. One was to avoid un-
necessarily contaminating the sensors, although they were sterilized (by autoclave) 
before implantation. The second was that by making a small slit in the rubber lid of 
the vials, and passing the sensor wire in this slit, a "pressure chamber" could easily 
be made, since no pressure chamber was available at our lab. During all lab meas-
urements, sensors behaved as expected. 
 
Figure 7 Illustration of the “noise” generated by external equipment. The larger spike-like 
noise is from the ventilator, the low-frequent oscillations starting at around 1265 are caused 
by the infusion pump. 
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During the animal experiments, we experienced large fluctuations (noise) in the 
recordings from the implanted sensors. This was explored in the lab, where sensors 
were submerged in saline for 24 hours. During measurements with these sensors, 
similar noise fluctuations were seen. It is speculated, that the reason for this noise 
is caused by volume conduction between the tracks and/or leads of the sensor. 
Ideally, silicone is not permeable to salts, but ions may be present in the saline 
solution causing this effect. However, this is purely speculation. It was not a con-
cern before the studies, but proved detrimental to the recording quality during 
experiments. All together, this suggests a sub-optimal sensor design for this appli-
cation. 
The pressure increases shown in Figure 6 are difficult to see directly from the in-
travesical pressure signal. If, however, the intravesical signal is amplified and offset 
artificially, a pattern similar to the bladder wall pressure emerges. This suggests 
that there is some form of non-voiding contractions occurring in the bladder. Look-
ing at the intravesical pressure signal, the contractions have an amplitude of ap-
proximately 1 cmH2O, and there are 8 contractions during a 200 s period. This cor-
responds very well with what was described by Drake et al. [13] even though they 
used excised guinea pig bladders. In addition to intravesical pressure, they meas-
ured relative movements of fixed points on the surface of the bladder; they did not 
look at intramural pressure. Data from this study support the existence of such 
non-voiding contractions, and suggest that localized intramural pressure can be as 
much as 20 cmH2O during these bladder waves. Looking at Figure 4, a similar pat-
tern of small (approximately 1 cmH2O in amplitude) pressure increases are seen in 
the intravesical pressure signal throughout the filling. The corresponding pressure 
fluctuations in intramural pressure have amplitudes of approximately 5 cmH2O. 
This corroborates the existence of local non-voiding contractions in the pig bladder. 
The sensors used in this experiment were not built with implantation as an intend-
ed application, but rather modified for use as implantable sensors. The sensor die is 
made of silicon and glass, and mounted on a ceramic substrate. The tracks and 
bond pads of the die are of aluminum; the soldering pads and tracks on the sub-
strate are gold. The die is connected to the substrate with gold wirebonds. The 
attached leads were made from biocompatible MP35N wire. The sensors show 
vulnerability to the harsh implanted environment at two points. One is the small 
pieces of copper used to connect the MP35N to the soldering pads, and the tin 
solder used for the attachment. The other is the aluminum tracks and bondpads on 
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the top of the sensor die. This is also where corrosion was seen to various degrees 
on all sensors. Despite this, sensor impedance remained constant over the cause of 
the experiments, even after reliable signals could not be obtained any longer. Also, 
the wire stress relief mechanism proved very efficient. The Teflon coated wire used 
may have helped in this as the connective tissue was not able to attach to the Tef-
lon. 
In the fully implanted pigs, 3 of 4 sensors had eroded out of the bladder wall after 3 
months. Post-terminal inspection showed that not all sensors were placed in the 
middle of the bladder wall, and that some were placed almost transverse to the 
bladder wall when the bladder was in the relaxed state, and parallel with wall as 
intended. It is expected that the number of eroded sensors could be reduced, had 
the sensors been placed in the middle of the wall, and parallel with it. An experi-
enced surgeon would be able to do this. 
In conclusion, problems with the animal model generally prevented recording of 
bladder pressures. However, one single experiment showed that recording is pos-
sible, and that the signal even can be used for automatic detection of contractions. 
Thickness of connective tissue encapsulation did not increase from 4 weeks to 3 
month, but was approximately 1 mm in all experiments independent of duration. In 
total, 4 of 10 sensors stayed in place, during the 4 weeks to 3 months duration of 
the experiments. This rate needs to be improved for application to become feasi-
ble. 
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Chapter VI 
General Discussion and Perspectives 
 
Discussion 
Conditional stimulation of the dorsal genital nerve would provide a near ideal mo-
dality to treat NDO. Side-effects known from medication would be eliminated, and 
efficacy is near 100 %. Financially, it is also more viable than medication [1]. Com-
pared to continuous stimulation, conditional stimulation provides higher bladder 
capacity [2], reduces the risk of habituation of the reflex loop, and reduces charge 
injection. This further reduces the risk of tissue damage, and prolongs electrode 
life. Finally, a signal can be given to the patient at the time of stimulation, to warn 
the patient that it is time to empty the bladder when convenient. This is particular-
ly important to patients, and may help them become completely dry. 
 
However, a sensor that can reliably detect the onset of contractions is needed. Part 
of the work of this thesis was to review the current state of the art regarding blad-
der sensing. Based on this, recommendations are given on preferred sensing mo-
dalities. The list of proposed methods include blood flow, O2 saturation, Near Infra-
red Spectroscopy (NIRS), bladder sound, bladder EMG, anal sphincter EMG, ure-
thral sphincter EMG, pelvic nerve ENG, sacral root ENG, pudendal nerve ENG, blad-
der pressure, skin potentials and bladder shape changes. Table 3 highlights the 
most important pros and cons of each method, from the perspective of being suit-
able for detecting the onset of bladder contractions.  
 
The review (study 1) showed that many methods, e.g. O2 saturation, blood flow 
and NIRS, are less suited for detecting the onset of bladder contractions, since they 
are all related to the restricted blood flow during contractions. Hence, deflections 
in these signals develop gradually with contraction duration, and for all these 
methods there is a considerable lag before contractions can be detected. ENG 
based methods are elegant in that they use the natural sensors of the bladder, but 
signal amplitude and noise from other (and larger) fibers in the same nerves makes 
this approach difficult. Velocity-selective recording could help improve on this, but 
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this requires a quite long electrode. Such an electrode would have to be implanted 
on a dorsal root, making the surgical procedure very invasive. 
 
Bladder EMG was measured with a complex setup; improvements in both equip-
ment and processing methods are needed before this modality can be considered a 
candidate. However, proxies of the bladder EMG often exist in NDO patients. Thus, 
external anal sphincter EMG and pelvic floor EMG were investigated by different 
groups. In acute trials, these modalities could be used to detect bladder contrac-
tions. However, the measurement setup is basically a noise-free environment, 
which is very different from the real life of patients, even if they are largely seden-
tary. Firstly, the equipment needs to be tested in chronic models, and secondly, the 
performance in a real life patient setting needs to be assessed. 
 
The most promising method is to base detection on bladder pressure. A few studies 
reported on catheter-based monitoring of intravesical pressure. Recordings were 
obtained for as long as 6 months. Risks of sensor migration, bladder rupture or 
simply encrustation of the catheter, all speak against this approach, but no conclu-
sive evidence that rule out catheter-based monitoring exists. Two independent 
groups have recently proposed devices for ambulatory monitoring of bladder pres-
sure. One device is intended for buoyant placement within the bladder lumen [3], 
while the other is placed surgically in a pouch between the detrusor and the 
urothelium [4, 5]. Both of the proposed systems are active systems that need to be 
recharged often. Further, they are placed at locations that may not be feasible for 
long term implantation, cf. the results of Koldewijn et al. [6].  
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In order to determine whether a pressure increase stems from an involuntary blad-
der contraction or a general pressure increase of the abdominal cavity as might 
occur when e.g. coughing or laughing, the differential pressure between abdomen 
and bladder needs to be evaluated. This can be done in a number of ways. Brindley, 
who was the first to apply this principle [7], made a “double-sided” sensor con-
nected to a mechanical switch based on a conducting fluid. The sensor consisted of 
two fluid-filled capsules on opposite sides of a common rigid wall, connected by 
tubes to a mechanical switch. One side faced the bladder, and one side faced the 
abdominal cavity. If pressure on the abdominal side exceeded pressure on the 
bladder side, a membrane in the switch would close a fluid duct, turning the switch 
off. Conversely, in pressure was highest on the bladder side, the membrane would 
be pressed away from the duct, allowing current to flow, thus turning the switch 
on. Hence, differential pressure was automatically obtained, and the switch could 
be used directly to control a stimulator. In case of involuntary bladder contractions 
the switch would turn on, but it would be left off in case of general abdominal 
pressure increases. The system worked well initially, however, in all four patients 
with the system, the sensors detached from the bladder within one year [6]. 
Differential pressure can also be computed from the signals from two separate 
sensors. This was done by e.g. Hansen et al. [8] and Fjorback et al. [9]. Both studies 
used catheters and external relative-type pressure sensors, to measure intravesical 
and abdominal pressure. The signals were fed into a computer, which computed 
the differential pressure, and from this signal a stimulator unit was controlled. In 
both studies this worked well, with an average of 16 and 12, respectively, inhibited 
bladder contractions without leakage. A thorough analysis of this method, and the 
ability to abolish nascent contractions has also been published by Fjorback et al. 
[10]. 
As demonstrated by the results of the studies of both Brindley and Koldewijn [6], 
the main problem with implantable pressure sensors has been that they erode 
away from their implantation site. Sensors placed on the bladder generally de-
tached, as did sensors placed between the detrusor and the urothelium. Sensors 
placed between the peritoneum and the detrusor provided the best chronic stabil-
ity for a sensor implant. In addition, the use of prolene (non-absorbable) sutures 
provided the most stable implants, a finding that was corroborated by Picha and 
Drake [11]. 
Based on this, a wireless sensor placed in the bladder wall, was hypothesized to be 
the optimal solution. It was speculated, that if it was possible to implant a sensor in 
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the bladder wall that was chronically stable, it would also be possible, and most 
likely easier, to implant a sensor somewhere in the abdominal cavity to monitor 
abdominal pressure. The differential bladder pressure could then be derived easily 
in a given stimulator implant. 
Another option is to use a differential sensor in a setup similar to that used by 
Brindley and Donaldson [7]. Two options for this principle will be described briefly. 
 One design would be a central membrane with a pressure chamber on 
each side. Such type of sensor is typically resistive. Resistive sensors are 
often wired, or alternatively equipped with embedded active electronics 
to measure the signal and send it out wirelessly. This is sketched in Figure 
8 (a). This type of sensor could be powered inductively by adding a coil 
(not shown), or an internal battery. Schemes for operating resistive sen-
sors without active electronics also exist, but are not well characterized.  
 Another possibility would be to use a modified LC tank sensor. In order to 
distinguish which side of the sensor is exposed to the highest pressure, a 
design with a cylindrical coil and capacitor plates on each end could be 
used. An iron bar could be attached to one plate, and the distance be-
tween the plates could be fixed. Movement of the bar further into the coil 
would increase inductance, while movement out of the coil would lower 
inductance. This is sketched in Figure 8 (b). (This principle of a variable in-
ductance was the first principle used for telemetric pressure sensors [12, 
13].) 
The benefit of such designs would be that the electronics needed in the stimulator 
unit could be made simpler, and that only one sensor is needed, which compared 
to the two needed for the indirect differential method, would reduce the risk of 
device failure. However, both designs would be more difficult to fabricate, and 
there would likely be a higher risk of erosion. In this scheme, the anchoring to the 
bladder would have to resist the force applied to the membrane facing the bladder, 
and although the forces are rather small, it would still promote, rather than pre-
vent, erosion.  
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 (a) (b) 
Figure 8 Sketches (cross-sections) of differential sensor designs. (a) Shows an example of a 
wireless active resistive-type sensor. It could be powered by a battery, or a coil for inductive 
powering could be added. (b) Illustrates a wireless passive LC-type sensor. An iron core is 
moved further into or out of the center of a coil (windings represented by small circles), 
depending on pressure, changing the inductance of the coil. This can be detected as a 
change in impedance using various techniques described later in this chapter. 
 
Based on these considerations, it was decided to focus on an absolute pressure 
sensor intended for implantation in the bladder wall. It is to be used in combination 
with a similar sensor for measuring abdominal pressure, enabling computation of 
the differential bladder pressure. There is, however, no clear evidence this is the 
optimal solution. 
 
The aim of study 2 was to develop an implantable pressure sensor capable of de-
tecting the onset of bladder contractions. The second study of this thesis demon-
strated, in an acute animal model, that this principle is feasible. A wired sensor 
coated with silicone to form a lens shape with diameter 13.6 mm and height 2 mm 
was made. Experiments were conducted in 6 pigs, where the sensor was placed in 
pouches in the bladder wall. Pouches were made at different positions (base and 
dome, medial and lateral), and with the sensor membrane both facing the bladder 
lumen and away from it. Across 114 contraction epochs of 90 second duration, 
contractions could be detected in 101. The correlation coefficient between the 
sensor signal and the intravesical pressure as measured by an external sensor was 
above 0.9 in 91 epochs. Keeping the explorative nature of the study in mind, these 
results are very promising. The peak pressures during evoked contractions were 
lower than expected. As a result, the threshold for detecting contractions was low-
ered from 10 cmH2O to 5 cmH2O. This was still considered to be of general applica-
bility, since the aim of the study was to investigate whether signals obtained from 
pouches in the bladder wall could be used equally well as the intravesical pressure. 
Given that intravesical pressure has been used successfully to detect the onset of 
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bladder contractions in humans [8], the point of interest was whether an equal 
performance could be obtained, and not whether the a certain threshold would be 
suitable for human application. Hence, number of detections, time delay of detec-
tion, and correlation with intravesical pressure were the parameters of interest. 
Good agreement in all three parameters for both sensor signals indicates that ei-
ther signal may be used. 
 
Chronic animal experiments were also conducted using a slightly modified sensor 
(study 3). For the chronic implantation, the sensor leads were made of four individ-
ual 0.3 mm diameter Teflon coated MP35N stranded wires. Reliable signals could 
be detected for only up to 3 weeks. This was due to problems with the sensor die, 
which was not developed for chronic implantation. When immersed in conducting 
(ionic) fluid for prolonged time, signals became unstable. Another problem was 
that of migration or erosion, as described by Koldewijn et al. [6]. In total, only four 
of ten sensors stayed in place during the chronic experiments. It was found that the 
sensors that stayed in place were implanted as intended, approximately in the 
middle of the detrusor, and an orientation parallel with the wall. Many parameters 
may have influenced migration. It is hypothesized, that the sensors that eroded 
were implanted either too superficially or too deep. This means that in order to 
erode, they needed only to penetrate the serous coat or the urothelium, not the 
detrusor fibers. Having the surgery done by an experienced surgeon, combined 
with a systematic investigation of different anchoring techniques is expected to 
increase this number of sensors that stay in place substantially. 
 
Other parameters that could be adjusted is size and surface texture of the sensor. 
This is a major discussion in itself, but a few points will be made here. It has been 
known at least since the 1980’s that the implant surface topography plays a signifi-
cant role in determining the foreign body response of an implant. [11, 14, 15]. De-
spite this, there has been more attention on surface chemistry than topography, or 
implant biomechanics in general, in the literature [16]. In addition, most research 
within the area of biocompatibility has traditionally been related to hard-tissue 
implants, i.e. implants into bones. However, some reviews of the importance of 
biomechanical factors on soft tissue implants have been published recently, e.g. 
Hilborn and Bjursten [16] and Helton et al. [17, 18]. Still, acknowledging the im-
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portance is not the same as understanding the interaction. An initial theoretical 
framework for this understanding was given by Helton et al. [17].  
The biomechanical interaction with tissue is now believed to be an equally im-
portant factor as surface chemistry, for achieving chronically stable implants. Me-
chanical loading causes bones to remodel and muscles to grow. Mechanical forces 
are also involved cellular signal transduction [16]. Hence, it would only be natural 
that biomechanics play an integral role in defining the foreign body response of an 
implant. 
For implanted devices, mechanical stresses may stem from several sources. Besides 
the tissue motion caused by movement in general, it could also be scratching over 
the area of an implanted sensor, pressure from lying on the area where the sensor 
is implanted, or from muscle contractions in the vicinity of the sensor. There seems 
to be general consensus that the most stable state for chronic implantation is that 
of maximal tissue adhesion, which also results in the thinnest capsule. This im-
portance of size and shape may for long have been an underappreciated factor, 
which has led to differing conclusions in several studies investigating surface topog-
raphy and chemistry. 
Generally, the smaller the sensor implant is, the lesser foreign body reaction it will 
cause [19]. However, the orientation of the implant is crucial in this relation. Most 
tissues have an extracellular matrix where the large collagen fibers are arranged 
mainly in layers. For such tissues, the height of the implant is much more critical 
than either length or width. This suggests that implants should be sheet-shaped, if 
possible, and placed parallel with fiber orientation [20].  
In order to reduce the response due to shear stresses experienced by an implant, it 
has been suggested to increase the surface area, thus reducing the force per unit 
area. In an extensive study, Picha and Drake showed that there were significant 
differences with respect to specific topography, implant site and implant anchoring 
[11]. Currently, surface topography in the nanoscale (irregular or patterns with 
features less than 100 nm) are considered most beneficial for cell adhesion and 
growth [21]. Such features can be made using a range of different techniques, all 
with their respective pros and cons, and different process requirements. For irregu-
lar patterns, the sol-gel thin film coating is relatively easy to apply [22]; for specific 
patterns techniques such as electron based lithography, nano-imprint lithography 
and many others may be used [23].  
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Based on the above, the following recommendation for a pressure sensor design is 
given. In the following, a passive wireless sensor is considered. This is due to the 
previous arguments for choosing this type of sensor. The sensor should be as small 
as possible, but this contradicts with the possibility of inductive powering. It was 
found that a sensor diameter (or side length) of approximately 1 cm would fulfill 
this requirement. Using MEMS techniques, a thickness of 0.5 mm should be possi-
ble. This is in line with the finding, that height is more critical than length or width. 
In order to achieve chronic stability, a textured or porous surface coating should be 
added. This could be done using the sol-gel technique, which preserves sensor 
roughness, and adds (unstructured) nanoscale roughness [24]. Preservation of 
sensor roughness may aid in anchoring the sensor, however, sharp edges should be 
avoided in order not to cause further trauma. 
In light of this, the sensor design employed in the chronic studies was not optimal. 
Even if a hermetically sealed MEMS sensor could not be manufactured, different 
techniques could be used to improve the chronic stability of the sensor. This was 
not possible within the limits of this project. 
 
In addition to the studies using wired sensors, wireless sensors were investigated. A 
wireless sensor was designed and realized, but did unfortunately not work due to 
problems with the fabrication process sequence. Owing to this, read-out circuitry 
was designed and the sensor system was analyzed by means of simulations (study 
4). It was found that distance between antenna and sensor is a critical factor, but 
that operation should at least be feasible for distances up to 12 mm. The wireless 
sensor is hypothesized to be superior to a wired sensor with respect to both migra-
tion and long term operation. This is because the lack of wires ensures that there 
are no pulling forces acting on the sensor. Similarly, because of the lack of wire 
connections, it can be completely sealed, so corrosion, lead detachment or similar 
events are avoided. Several operating principles have been described in the litera-
ture. For use with a fully implantable system, the problem is keeping the circuitry 
simple and keeping power consumption low. The system described in this study 
should fulfill these requirements. 
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Perspectives and future work 
 
The most important single step is to make a sensor that is not only biocompatible, 
but can sustain operation for a prolonged period of time in the harsh environment 
that the body is. This imposes that all ‘internal’ wiring of the sensor, e.g. strain 
gauges and wire bonds if they exist, should be hermetically sealed. The sensor used 
in this work was only covered with silicone, and although the impermeability to 
salts should create a sustained osmotic pressure ‘out of’ the sensor [25], strange 
behavior of the recorded signal was noticed after 3 weeks of implantation. This was 
even if only minimal corrosion was seen on post experimental sensor retrieval. The 
only explanation found was that current paths altering the behavior of the sensor 
arise through the body fluids. In light of this, a simple LC-tank type wireless sensor 
may prove superior, since it can be sealed better. In addition to this, the wireless 
sensor will, at least theoretically, have a reduced risk of migration, making is a very 
attractive option. 
 
Once a proper sensor is constructed, there are still two unknowns that need to be 
clarified. They are firstly, if the sensor will stay in place chronically, and secondly, if 
the sensor performance remains intact during this period. In case both of the 
above can be confirmed, a fully implantable system for use in humans can be 
made. Given such a system, the next step is to investigate whether bladder con-
tractions can be detected reliably. Pressure increases may be detected due to non-
voiding contractions, coughing, laughing, changes in position and several other 
events. Characteristic features (e.g. morphology, rate of increase) of bladder con-
tractions may be found, that can help distinguish them from the other mentioned 
events. Finally, if proof-of-concept is shown in a pilot study, larger studies are still 
needed to show the general efficacy of such a system. 
 
In conclusion, it was shown that it is possible to detect bladder contractions using a 
pressure sensor placed in the bladder wall. Positive results were obtained in acute 
experiments, but only for up to 3 weeks in chronic experiments. Evidence from 
laboratory measurements indicate that these problems were with the sensor, and 
not due to the host response to implantation. One natural bladder contraction was 
recorded after 3 weeks of implantation. A slow filling of the bladder was done, until 
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a distention-evoked reflex contraction occurred. The contraction was detected 
using an automatic detection algorithm based on the signal from the implanted 
sensor. Although there is a cascade of developments needed before a neural pros-
thesis can be realized, this demonstrates proof-of-concept for this approach. 
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